HUP0301422A2 - Ösztrogén hatású szereket tartalmazó gyógyászati készítmények - Google Patents

Ösztrogén hatású szereket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0301422A2
HUP0301422A2 HU0301422A HUP0301422A HUP0301422A2 HU P0301422 A2 HUP0301422 A2 HU P0301422A2 HU 0301422 A HU0301422 A HU 0301422A HU P0301422 A HUP0301422 A HU P0301422A HU P0301422 A2 HUP0301422 A2 HU P0301422A2
Authority
HU
Hungary
Prior art keywords
group
hydrogen atom
alkyl
general formula
ethers
Prior art date
Application number
HU0301422A
Other languages
English (en)
Inventor
Eric Joel Benjamin
Wendy Ann Dulin
Jiwaji Gulabrao Suryawanshi
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0301422A2 publication Critical patent/HUP0301422A2/hu
Publication of HUP0301422A3 publication Critical patent/HUP0301422A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

A találmány új gyógyszerészeti hordozó- vagy segédanyagrendszerre ésorális gyógyászati készítményekre vonatkozik, amelyek hatóanyagkéntraloxifent, amoxifent, droloxifent, arzoxifent vagy CP 336156-ot vagyezek analógjait vagy (I) vagy (II) általános képletű vegyületeket - aképletekben Z jelentése (a), (b) vagy (c) általános képletű csoport,ahol R1 jelentése hidrogénatom, hidroxilcsoport vagy annak észtereivagy alkil-éterei, benzoil-oxi-csoport vagy halogénatom vagyhalogénezett éterek; R2, R3, R4, R5 és R6 jelentése hidrogénatom,hidroxilcsoport vagy annak és észterei vagy alkil-éterei, halogénatom,vagy halogénezett éterek, cianocsoport, alkilcsoport vagy trifluor-metil-csoport, azzal a megkötéssel, hogy amikor R1 jelentésehidrogénatom, R2 jelentése hidroxilcsoporttól eltérő; X jelentésehidrogénatom, alkilcsoport, cianocsoport, nitrocsoport, tritfluor-metil-csoport vagy halogénatom; n értéke 1, vagy 3; Y jelentése (d)általános képletű csoport, ahol R7 és R8 elentése hidrogénatom, 1-6szénatomos alkilcsoport vagy fenilcsoport, vagy együtt adott esetbenhelyettesített nitrogéntartalmú gyűrűt alkotnak - vagy a vegyületekgyógyászatilag elfogadható sóját és gyógyszerészeti töltőanyagok,csúsztatóanyagok, kenőanyagok, nedvesítőszerek és antioxidánsok közülválasztott segédanyagot tartalmaznak. Ó
HU0301422A 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents HUP0301422A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21619200P 2000-07-06 2000-07-06
PCT/US2001/020993 WO2002003987A2 (en) 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents

Publications (2)

Publication Number Publication Date
HUP0301422A2 true HUP0301422A2 (hu) 2003-09-29
HUP0301422A3 HUP0301422A3 (en) 2006-07-28

Family

ID=22806095

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301422A HUP0301422A3 (en) 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents

Country Status (26)

Country Link
US (2) US20020031548A1 (hu)
EP (1) EP1309327B1 (hu)
JP (1) JP2004502733A (hu)
KR (2) KR100862174B1 (hu)
CN (2) CN1450895A (hu)
AR (1) AR029538A1 (hu)
AT (1) ATE453391T1 (hu)
AU (2) AU7174101A (hu)
BR (1) BR0112242A (hu)
CA (1) CA2415058A1 (hu)
CY (1) CY1109915T1 (hu)
DE (1) DE60140945D1 (hu)
DK (1) DK1309327T3 (hu)
EA (1) EA006386B1 (hu)
ES (1) ES2336304T3 (hu)
HU (1) HUP0301422A3 (hu)
IL (2) IL153647A0 (hu)
MX (1) MXPA02012891A (hu)
NO (1) NO20030030L (hu)
NZ (1) NZ523330A (hu)
PL (1) PL204866B1 (hu)
PT (1) PT1309327E (hu)
SI (1) SI1309327T1 (hu)
TW (1) TWI294777B (hu)
WO (1) WO2002003987A2 (hu)
ZA (1) ZA200301004B (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
KR20050010886A (ko) * 2002-06-13 2005-01-28 와이어쓰 바제독시펜 치료 방식
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
AU2005206137A1 (en) * 2004-01-13 2005-08-04 Wyeth Treatment of aromatase inhibitor therapy-related osteoporosis
UA86055C2 (ru) * 2004-04-07 2009-03-25 Уайет Кристаллическая форма в базедоксифена ацетата
TWI346105B (en) 2004-04-07 2011-08-01 Wyeth Corp Crystalline polymorph of bazedoxifene acetate
AU2005232640B2 (en) * 2004-04-08 2011-07-28 Wyeth Bazedoxifene acetate solid dispersion formulations
RU2006132181A (ru) * 2004-04-08 2008-05-20 Вайет (Us) Базедоксифен аскорбат в качестве селективного модулятора рецептора эстрогена
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN100358517C (zh) * 2004-09-28 2008-01-02 马晶 一种枸橼酸他莫昔芬口腔崩解片及其制备方法
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
DK1729735T3 (da) * 2004-11-10 2007-10-08 Teva Pharma Fremgangsmåde til fremstilling af sammenpressede, faste doseringsformer, som er velegnede til brug sammen med lægemidler med lav vandoplöselighed og sammenpressede, faste doseringsformer fremstillet derved
EP1787642A1 (en) * 2004-11-10 2007-05-23 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
AU2006229869A1 (en) * 2005-03-31 2006-10-05 Wyeth O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
PE20070188A1 (es) * 2005-06-29 2007-03-16 Wyeth Corp Formulaciones de estrogenos conjugados y bazedoxifeno
CA2620174A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
TW200836774A (en) * 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
EP2197423B1 (en) * 2007-10-16 2014-12-03 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
US20110159084A1 (en) * 2008-04-02 2011-06-30 Dr. Reddy's Laboratories Ltd. Raloxifene pharmaceutical formulations
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
CA2775599A1 (en) 2009-10-27 2011-05-12 Wyeth Llc Bazedoxifene formulations with antioxidants
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
TWI580444B (zh) 2012-06-05 2017-05-01 武田藥品工業股份有限公司 固態製劑
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
EP3626713B1 (en) 2014-02-13 2021-09-29 Incyte Corporation Cyclopropylamines for use as lsd1 inhibitors
CN106488915B (zh) 2014-02-13 2020-10-02 因赛特公司 作为lsd1抑制剂的环丙胺
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US20160287573A1 (en) 2015-04-02 2016-10-06 Theravance Biopharma R&D Ip, Llc Combination dosage form of a mu opioid receptor antagonist and an opioid agent
AU2016243939B2 (en) 2015-04-03 2020-09-03 Incyte Holdings Corporation Heterocyclic compounds as LSD1 inhibitors
EA035534B1 (ru) 2015-08-12 2020-06-30 Инсайт Корпорейшн Соли ингибитора lsd1
WO2018010543A1 (zh) * 2016-07-11 2018-01-18 武汉朗来科技发展有限公司 一种用于口服固体制剂的复合崩解剂体系及含有该复合崩解剂体系的口服固体制剂
KR101683193B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
KR101683192B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
CN107951034B (zh) * 2017-12-01 2021-03-23 郑州拓洋生物工程有限公司 维生素泡腾制剂及其制备方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
RU2732291C1 (ru) * 2020-02-13 2020-09-15 Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") Лекарственный препарат на основе травы алтея лекарственного для лечения простудных и острых респираторных заболеваний

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3552727A (en) * 1968-09-18 1971-01-05 American Air Filter Co Gas scrubbing apparatus
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3029742B2 (ja) * 1992-08-20 2000-04-04 株式会社東芝 画像補正装置
JPH0674903A (ja) * 1992-08-26 1994-03-18 Sumitomo Metal Ind Ltd 平板状被検出材の微小欠陥検出方法及び装置
FR2698788B1 (fr) 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
US5342133A (en) * 1992-12-23 1994-08-30 Hewlett-Packard Company Paper moving system for a printer/plotter
US5332727A (en) 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL117276A (en) * 1995-02-28 2001-10-31 Lilly Co Eli Benziophene compounds, their preparation and their related compositions
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5919800A (en) 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
NZ314601A (en) 1996-04-19 1999-09-29 American Home Prod 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives as estrogenic agents and pharmaceutical compositions
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
JP2001519410A (ja) 1997-10-15 2001-10-23 アメリカン・ホーム・プロダクツ・コーポレイション 新規なアリールオキシ−アルキル−ジアルキルアミン
JP2002521322A (ja) * 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法

Also Published As

Publication number Publication date
TWI294777B (en) 2008-03-21
EA006386B1 (ru) 2005-12-29
KR100894027B1 (ko) 2009-04-22
MXPA02012891A (es) 2003-10-24
NO20030030L (no) 2003-03-03
PT1309327E (pt) 2010-02-23
WO2002003987A3 (en) 2002-07-11
NO20030030D0 (no) 2003-01-03
EP1309327A2 (en) 2003-05-14
PL204866B1 (pl) 2010-02-26
JP2004502733A (ja) 2004-01-29
BR0112242A (pt) 2003-06-24
DK1309327T3 (da) 2010-04-26
ATE453391T1 (de) 2010-01-15
WO2002003987A2 (en) 2002-01-17
ZA200301004B (en) 2004-05-05
US20020031548A1 (en) 2002-03-14
CY1109915T1 (el) 2014-09-10
AR029538A1 (es) 2003-07-02
KR20070110454A (ko) 2007-11-16
IL153647A0 (en) 2003-07-06
EP1309327B1 (en) 2009-12-30
AU2001271741B2 (en) 2006-10-19
SI1309327T1 (sl) 2010-03-31
CN1450895A (zh) 2003-10-22
HUP0301422A3 (en) 2006-07-28
KR100862174B1 (ko) 2008-10-09
AU7174101A (en) 2002-01-21
KR20030023689A (ko) 2003-03-19
NZ523330A (en) 2005-07-29
EA200300122A1 (ru) 2003-06-26
US20080269198A1 (en) 2008-10-30
CA2415058A1 (en) 2002-01-17
CN101416949A (zh) 2009-04-29
IL153647A (en) 2011-03-31
US7759386B2 (en) 2010-07-20
PL365875A1 (en) 2005-01-10
DE60140945D1 (de) 2010-02-11
ES2336304T3 (es) 2010-04-12

Similar Documents

Publication Publication Date Title
HUP0301422A2 (hu) Ösztrogén hatású szereket tartalmazó gyógyászati készítmények
UY27384A1 (es) Analogos de prostaglandina
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
IL108602A0 (en) N-alkyl-2-substituted atp analogues, their preparation and pharmaceutical compositions containing them
HUP0100280A2 (hu) Pirrolo-, tieno-, furano- és pirazolo [3,4d] piridazonok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények
AU4306796A (en) Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
ZA200505273B (en) Novel compound
HUP0103096A2 (hu) 2-Fenil-1-[4-(2-amino-etoxi)-benzil]-indol-származékok és ösztrogének kombinációját tartalmazó gyógyszerkészítmények
DE60005502D1 (de) 4'-c-ethynyl-purin-nukleoside
HUP9902454A2 (hu) Szubsztituált 1,2,3,4-tetrahidronaftalin-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
RU2010154417A (ru) Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
AR032066A1 (es) Agente para tratamiento terapeutico y profilactico del dolor neuropatico
HRP20070030T3 (en) Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them
HUP0401018A2 (hu) 2H-1-benzopirán-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
HU9902784D0 (en) New indan-1-ol compounds, process for their preparation and pharmaceutical compositions containing them
HUP0001773A2 (hu) Szubsztituált tetrahidropiridinszármazékok, eljárás előállításukra, továbbá a vegyületeket tartalmazó gyógyászati készítmények
DE60220779D1 (de) Tetrahydropyridyl-alkyl-heterozykle, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees